EQS-News: Marinomed Biotech AG Announces Strategic Partnership and Worldwide Licensing for Marinosolv® Technology in Inhalation Therapy

EQS-News: Marinomed Biotech AG / Key word(s): Alliance
   Marinomed Biotech AG Announces Strategic Partnership and Worldwide
   Licensing for Marinosolv® Technology in Inhalation Therapy

   19.05.2026 / 07:58 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

    Marinomed Biotech AG Announces Strategic Partnership and Worldwide
   Licensing for Marinosolv® Technology in Inhalation Therapy

     • Marinomed signs term sheet with Phargentis SA for a worldwide
       exclusive license of the Marinosolv® technology platform for an
       inhalation formulation.
     • Partnership includes fee-for-service development, long-term milestone
       payments, and future royalties on product sales.
     • The collaboration leverages Marinomed’s expertise to enhance
       solubility and bioavailability of a specialized respiratory
       therapeutic.

    

   Korneuburg, Austria, May 19^th, 2026 – Marinomed Biotech AG (VSE:MARI), a
   dynamic biopharmaceutical company, today announced the signing of a term
   sheet with Phargentis SA. The term sheet contains the worldwide licensing
   of the proprietary Marinosolv® technology platform for the development of
   a high-performance formulation with a combination of different active
   pharmaceutical ingredients specifically designated for inhalation.

   Under the terms of the agreement, Marinomed will provide specialized
   formulation services and technical expertise to develop a respiratory
   therapeutic utilizing the Marinosolv® platform. This technology is
   designed to significantly increase the solubility and bioavailability of
   hydrophobic compounds, enabling more effective delivery to the lungs and
   potentially reducing the required dosage for patients.

   The financial structure of the partnership includes immediate
   fee-for-service components for the initial development phases.
   Furthermore, Marinomed is eligible to receive milestone payments tied to
   specific technical and clinical achievements throughout the development
   lifecycle, spanning several years. Upon successful commercialization, the
   agreement also stipulates the payment of royalties on net sales of the
   resulting product.

   "This agreement marks another significant milestone in our strategy to
   monetize the Marinosolv® platform beyond our own internal pipeline," said
   Andreas Grassauer, CEO of Marinomed. "By applying our technology to
   inhalation therapies, we are addressing a critical need for better
   delivery of poorly soluble drugs in respiratory medicine. This partnership
   not only validates the versatility of our patent portfolio but also
   provides a sustainable revenue stream through services, milestones, and
   future royalties."

   The Marinosolv® technology has already demonstrated its capability in
   various ophthalmic and nasal applications. This latest expansion into
   inhalation underscores the platform’s potential to revolutionize treatment
   paradigms across multiple therapeutic areas where drug solubility remains
   a barrier to clinical success.

    

   About Marinosolv®

   Marinosolv® is Marinomed’s proprietary technology platform designed to
   increase the solubility of hardly soluble compounds. This enables the
   development of aqueous formulations for sensitive tissues such as the
   eyes, nose, and lungs without the need for harsh solvents or
   preservatives, thereby improving both efficacy and local tolerability.

    

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline. The Company develops innovative
   patent-protected products based on the Marinosolv® platform. The
   Marinosolv® technology improves the solubility and bioavailability of
   hardly soluble compounds and is used to develop new therapeutics for
   autoreactive immune disorders. The Company is headquartered in Korneuburg,
   Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
   further information, please visit: [1]https://www.marinomed.com.

    

   About Phargentis SA

   Phargentis, founded in 2015 and headquartered in Lugano Switzerland,
   develops Generic and innovative Super Generic products for the respiratory
   market with a strong focus on COPD and Asthma. Phargentis is an agile
   company that leverages robust global partnerships to execute a unique
   Early Market Entry strategy for Generics and global out-licensing for its
   diverse, competitive portfolio. Phargentis is co-owned by Chemholding
   (Switzerland), Helm Swiss (Switzerland) and Pharmaxis (Dubai). Its
   flagship product is generic Tiotropium bromide DPI, the fully
   interchangeable generic version of the world’s first-line COPD treatment,
   achieved European sales and is being planned to launch in other key
   markets.

    

   For further inquiries contact:

   Marinomed Biotech AG         
   PR: Luca Horinek
   IR.: Tobias Meister
   T: +43 2262 90300 158
   E-Mail: [2][email protected]
   E-Mail: [3][email protected]

    

   Disclaimer

   The new shares and subscription rights have not been and will not be
   registered under foreign securities laws – in particular under the U.S.
   Securities Act of 1933, as amended ("Securities Act") – with foreign
   securities authorities and may not be offered or sold, in particular in
   the United States of America ("US"), without registration or an exemption
   from the registration requirements under the Securities Act. This
   communication is not intended for distribution to or within the US and may
   not be distributed or forwarded to publications with general circulation
   in the US. This communication constitutes neither an offer to sell nor an
   invitation to subscribe for or purchase securities in any jurisdiction in
   which such an offer or such an invitation would be unlawful.

   ══════════════════════════════════════════════════════════════════════════

   19.05.2026 CET/CEST This Corporate News was distributed by [4]EQS Group

   View original content: [5]EQS News

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      [email protected]
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
                Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
                Market)
   EQS News ID: 2329490


    
   End of News EQS News Service


   2329490  19.05.2026 CET/CEST

   https://eqs-cockpit.com/cgi-bin/fncls2.ssx?fn=show_t_gif&application_id=2329490&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2329490&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   2. mailto:[email protected]
   3. mailto:[email protected]
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2329490&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=150d4456ab8cdf771506c5ac542ad01a&application_id=2329490&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT |

print